352 related articles for article (PubMed ID: 23542820)
1. Mesenchymal stem cells and neuroregeneration in Parkinson's disease.
Glavaski-Joksimovic A; Bohn MC
Exp Neurol; 2013 Sep; 247():25-38. PubMed ID: 23542820
[TBL] [Abstract][Full Text] [Related]
2. Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors.
Glavaski-Joksimovic A; Virag T; Chang QA; West NC; Mangatu TA; McGrogan MP; Dugich-Djordjevic M; Bohn MC
Cell Transplant; 2009; 18(7):801-14. PubMed ID: 19796495
[TBL] [Abstract][Full Text] [Related]
3. Can mesenchymal stem cells reduce vulnerability of dopaminergic neurons in the substantia nigra to oxidative insult in individuals at risk to Parkinson's disease?
Datta I; Bhonde R
Cell Biol Int; 2012 Jul; 36(7):617-24. PubMed ID: 22417707
[TBL] [Abstract][Full Text] [Related]
4. Restorative strategies for the dopaminergic nigrostriatal projection pathway.
Nikkhah G
Acta Neurochir Suppl; 2013; 117():79-85. PubMed ID: 23652661
[TBL] [Abstract][Full Text] [Related]
5. Cell transplantation in the damaged adult brain.
Jaber M; Benoit-Marand M; Prestoz L; Gaillard A
Rev Neurol (Paris); 2013 Nov; 169(11):838-43. PubMed ID: 24112517
[TBL] [Abstract][Full Text] [Related]
6. Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.
Chen W; Huang Q; Ma S; Li M
ACS Chem Neurosci; 2019 Feb; 10(2):839-851. PubMed ID: 30346716
[TBL] [Abstract][Full Text] [Related]
7. Pluripotent stem cells as new drugs? The example of Parkinson's disease.
Preynat-Seauve O; Burkhard PR; Villard J; Zingg W; Ginovart N; Feki A; Dubois-Dauphin M; Hurst SA; Mauron A; Jaconi M; Krause KH
Int J Pharm; 2009 Nov; 381(2):113-21. PubMed ID: 19782880
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic differentiation of neural progenitors derived from placental mesenchymal stem cells in the brains of Parkinson's disease model rats and alleviation of asymmetric rotational behavior.
Park S; Kim E; Koh SE; Maeng S; Lee WD; Lim J; Shim I; Lee YJ
Brain Res; 2012 Jul; 1466():158-66. PubMed ID: 22634376
[TBL] [Abstract][Full Text] [Related]
9. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells.
Isacson O; Bjorklund LM; Schumacher JM
Ann Neurol; 2003; 53 Suppl 3():S135-46; discussion S146-8. PubMed ID: 12666105
[TBL] [Abstract][Full Text] [Related]
10. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic differentiation using pluripotent stem cells.
Momčilović O; Montoya-Sack J; Zeng X
J Cell Biochem; 2012 Dec; 113(12):3610-9. PubMed ID: 22807388
[TBL] [Abstract][Full Text] [Related]
12. Neurotrophic factors for the treatment of Parkinson's disease.
Chiocco MJ; Harvey BK; Wang Y; Hoffer BJ
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S321-8. PubMed ID: 18267258
[TBL] [Abstract][Full Text] [Related]
13. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.
Brizard M; Carcenac C; Bemelmans AP; Feuerstein C; Mallet J; Savasta M
Neurobiol Dis; 2006 Jan; 21(1):90-101. PubMed ID: 16084732
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease.
Chao YX; He BP; Tay SS
J Neuroimmunol; 2009 Nov; 216(1-2):39-50. PubMed ID: 19819031
[TBL] [Abstract][Full Text] [Related]
15. Concise review: therapeutic strategies for Parkinson disease based on the modulation of adult neurogenesis.
Geraerts M; Krylyshkina O; Debyser Z; Baekelandt V
Stem Cells; 2007 Feb; 25(2):263-70. PubMed ID: 17082225
[TBL] [Abstract][Full Text] [Related]
16. Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson's disease.
Schwerk A; Altschüler J; Roch M; Gossen M; Winter C; Berg J; Kurtz A; Akyüz L; Steiner B
Regen Med; 2015 May; 10(4):431-46. PubMed ID: 26022763
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease.
Venkatesh K; Sen D
Curr Stem Cell Res Ther; 2017; 12(4):326-347. PubMed ID: 27842480
[TBL] [Abstract][Full Text] [Related]
18. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease.
Lindvall O; Kokaia Z
Trends Pharmacol Sci; 2009 May; 30(5):260-7. PubMed ID: 19362379
[TBL] [Abstract][Full Text] [Related]
19. Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice.
Cui YF; Hargus G; Xu JC; Schmid JS; Shen YQ; Glatzel M; Schachner M; Bernreuther C
Brain; 2010 Jan; 133(Pt 1):189-204. PubMed ID: 19995872
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic cells, derived from a high efficiency differentiation protocol from umbilical cord derived mesenchymal stem cells, alleviate symptoms in a Parkinson's disease rodent model.
Shetty P; Thakur AM; Viswanathan C
Cell Biol Int; 2013 Feb; 37(2):167-80. PubMed ID: 23339105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
